Skip to content

A Feasibility Clinical Study on DNA/RNA Multi-omics Predictive Model for Optimized Embryo Transfer

A Feasibility Clinical Study on DNA/RNA Multi-omics Predictive Model for Optimized Embryo Transfer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118331
Enrollment
Unknown
Registered
2026-02-04
Start date
2026-02-09
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Experimental group:The DNA/RNA multi-omics predictive model predicts and scores euploid embryos for ongoing pregnancy success, prioritizing higher-scoring embryos for transfer.
Control group:Euploid embryo transfer by standard PGT-A selection

Sponsors

Reproductive Medicine Center, Shanxi Provincial Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. For patients undergoing PGT-A treatment, the indications for PGT-A treatment include advanced maternal age (>= 35 years old), or/and two or more recurrent spontaneous abortions of unknown cause, or/and repeated implantation failures (transplantation >= 3 times and at least 3 high-quality embryos failed to result in clinical pregnancy). 2.At least 2 euploid blastocysts, and morphological rating (4BC/4CB or above) 3.Voluntary participation in this study and signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with uterine cavity abnormalities, such as congenital uterine malformations (unicornuate, bicornuate or didelphic uterus); untreated uterine septum, submucosal fibroids or endometrial polyps; or history of moderate to severe intrauterine adhesions. 2.Severe hydrosalpinx with tubal fluid reflux into uterine cavity that remains untreated. 3.Patients planning to undergo PGT-SR (preimplantation genetic testing for structural rearrangements) or PGT-M (preimplantation genetic testing for monogenic disorders) or sex selection due to Y chromosome microdeletion. 4.Patients using donor sperm or donor eggs to achieve pregnancy. 5.Untreated severe medical or surgical conditions. 6.Vulnerable populations, including individuals with mental illness, cognitive impairment, critically ill patients, minors, pregnant women, etc. 7.Other conditions that the investigator deems unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Ongoing pregnancy rate;

Secondary

MeasureTime frame
Clinical pregnancy rate;Early miscarriage rate;

Countries

China

Contacts

Public ContactXueqing Wu

Reproductive Medicine Center, Shanxi Provincial Maternal and Child Health Hospital

wuxueqq@hotmail.com+86 351 336 0725

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026